Sysmex Canada introduces new hematology analyzers

Sysmex Canada, providers of automated hematology and urinalysis diagnostic testing, has launched the new XN-L Series for testing in smaller analytic devices.

The XN-L is designed for smaller healthcare organizations that do not need the larger XN-Series analyzer, making the system affordable while still maintaining quality results. The system integrates with laboratories that require a high quality backup.

"We are pleased to be able to offer the XN-L Series of hematology analyzers to the Canadian healthcare market," said Carl Rocha, general manager at Sysmex. "The XN-L Series complements our flagship XN-Series analyzers by serving the lower volume end of the healthcare spectrum. The XN-L can also serve as a high-quality backup for larger labs, especially those with an XN-Series analyzer, offering standardization of reagents and controls across all test volume segments."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.